Cross-licensing of prescription and non-prescription drugs, transfer of manufacturing of preservative free ophthalmic products, and potential collaboration on the Russian market – these are the key components of the partnership signed by companies JGL and Polpharma SA. Through the collaboration with Polpharma Group, being represented in 35 countries, products of the JGL will be available on the Polish and other European markets. In addition, a part of Polpharma’s portfolio will be manufactured in JGL’s plants in Rijeka and sold on the Croatian and other European markets.
“We are very pleased about the partnership between our two great companies. This collaboration demonstrates JGL’s strength and competitiveness on the global market and competence of our employees, especially in the field of ophthalmology which is our core therapeutic area,” said Mislav Vučić, the CEO of JGL, who signed the contract with Markus Sieger, the CEO of Polpharma Group, at the headquarters of the Polish company.
“Polpharma has defined ophthalmology as one of our main growth therapeutic areas, where we have invested during the last few years in the development of new advanced products and industrial capabilities. Through yet another cooperation in ophthalmology, with JGL, we make our offer in this area even more compelling for our clients and patients. This will also allow us to enter new markets and expand our territory in the European Union. I believe that this is a great start of a very promising cooperation.” stated Markus Sieger.
Experts from both companies have already started the joint implementation of the agreed projects, with the first results of the cooperation already expected in the business year 2019.